Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 26;5(2):602-606.
doi: 10.1182/bloodadvances.2020003554.

CAR T cells better than BiTEs

John C Molina  1   2 , Nirali N Shah  1
Affiliations

CAR T cells better than BiTEs

John C Molina et al. Blood Adv. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: The authors declare no competing financial interests.

References

    1. Gaudichon J, Jakobczyk H, Debaize L, et al. . Mechanisms of extramedullary relapse in acute lymphoblastic leukemia: Reconciling biological concepts and clinical issues. Blood Rev. 2019;36:40-56. - PubMed
    1. DeAngelo DJ, Jabbour E, Advani A. Recent advances in managing acute lymphoblastic leukemia. Am Soc Clin Oncol Educ Book. 2020;40:330-342. - PubMed
    1. Brown P, Inaba H, Annesley C, et al. . Pediatric acute lymphoblastic leukemia, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18(1):81-112. - PubMed
    1. Slaney CY, Wang P, Darcy PK, Kershaw MH. CARs versus BiTEs: A comparison between T cell-redirection strategies for cancer treatment. Cancer Discov. 2018;8(8):924-934. - PubMed
    1. Topp MS, Gökbuget N, Zugmaier G, et al. . Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol. 2014;32(36):4134-4140. - PubMed

Substances